COPD Drugs Market in China 2016-2020

Table of Contents

PART 01: Executive summary

• Highlights

PART 02: Scope of  the report

• Market overview
• Top-vendor offerings

PART 03: Market research methodology

• Research methodology
• Economic indicators

PART 04: Introduction

• Key market highlights

PART 05: COPD: An overview

• Causes and risk factors
• Symptoms
• Diagnosis
• Management

PART 06: China-Country snapshot

• Social and economic conditions
• Healthcare reform
• Healthcare infrastructure

PART 07: Pharmaceutical industry in China

• Market overview
• Major pharmaceutical vendors in China
• Opportunities for global and local vendors
• Drug approval process in China

PART 08: Drug pricing and reimbursement

• Market-driven drug pricing strategy
• Scrutinization of illegal pricing of drugs

PART 09: Pipeline portfolio

PART 10: Global respiratory drugs market

• Market overview
• Global COPD drugs market

PART 11: Market landscape

• COPD drugs market in china
• Five forces analysis

PART 12: Market segmentation by drug class

• Bronchodilators
• PDE-4 inhibitors
• Steroids
• Combination therapies
• Other medications

PART 13: Market drivers

• Increase in prevalence of smoking
• Rise in healthcare expenditure
• Increase in environmental pollution

PART 14: Impact of drivers

PART 15: Market challenges

• Low diagnosis rate
• Alternative therapies
• High cost of therapy

PART 16: Impact of drivers and challenges

PART 17: Market trends

• Rise in awareness programs
• Increased focus on combination therapies
• Rise in R&D by global companies

PART 18: Vendor landscape

• Competitive scenario
• AstraZeneca
• Boehringer Ingelheim
• GSK
• Merck
• Novartis
• Other prominent vendors

PART 19: Appendix

• List of abbreviations

PART 20: Explore Technavio